Cartalax Dosage Guide: Protocols, Calculator & Safety

Beginner Cartalax Protocol (first joint-focused cycle)

• Product form: 20 mg oral capsule from a vendor with third-party HPLC and certificate of analysis.
• Dose: 1 capsule (20 mg) once daily, sublingual or oral on empty stomach 30–45 minutes before breakfast.
• Duration: 10 consecutive days, then stop.
• Washout: 60 days minimum before repeat cycle.
• Monitoring: Baseline subjective pain score (VAS 0–10), morning stiffness duration, range-of-motion assessment for affected joints. Track daily during cycle and 4 weeks post-cycle. Optional: WOMAC knee/hip score if interested in more systematic tracking.
• Continue all existing joint therapy. Do not stop NSAIDs, topical agents, or physical therapy to test Cartalax alone.
• Stop criteria: Worsened joint pain, new joint swelling, rash, persistent headache, or any unexpected symptom.
• Setting expectations: Most users report modest improvement — mild pain reduction, slightly better range of motion. Do not expect transformative relief. Structural cartilage does not regenerate from a 10-day peptide cycle.
• Focus on fundamentals: If overweight, weight loss will deliver more joint benefit than any peptide. If sedentary, structured exercise will too. Treat Cartalax as an experimental adjunct to these, not a substitute.

Intermediate Cartalax Protocol (experienced bioregulator user)

• Product form: 20 mg oral capsule or lyophilised synthetic AEDL (requires reconstitution).
• Dose: 20 mg oral daily OR 2–5 mg SC daily.
• Duration: 10 consecutive days per cycle.
• Cycling: Twice yearly — spring and autumn.
• Rotation: Space Cartalax from other Khavinson peptides by at least 2 months.
• Co-dosing with BPC-157 and/or TB-500: Many users stack Cartalax with BPC-157 250 mcg SC daily and/or TB-500 2–5 mg weekly for joint-focused peptide therapy. Safety from an interaction standpoint is acceptable; synergy is theoretical.
• Monitoring: Monthly pain VAS, range-of-motion measurements, activity tracking. Annual imaging if moderate-severe OA (X-ray knee or hip).
• Stack integration: Continue evidence-graded joint therapy. Bioregulator is experimental layer.
• What to expect: Modest subjective improvements. Some users report cumulative benefit over multiple cycles in the same year. Cartilage regeneration claims should be treated sceptically.
• Cost honesty: Annual Cartalax cycling costs 150–300 USD. A lower-body strength training programme, weight loss programme, or certified physical therapy visit produces more measurable joint benefit.

Advanced Cartalax Protocol (Khavinson-style joint rotation)

For users with 6+ months of Khavinson experience and stable baseline joint status.

• Annual rotation:
  • Month 1, Days 1–10: Cartalax 20 mg oral/sublingual daily.
  • Months 2–3: Washout.
  • Month 4, Days 1–10: Epitalon 5–10 mg SC daily.
  • Months 5–6: Washout.
  • Month 7, Days 1–10: Thymogen 100 mcg SC daily.
  • Months 8–9: Washout.
  • Month 10, Days 1–10: Cartalax repeat cycle with concurrent BPC-157 250 mcg SC daily for 30 days.
  • Months 11–12: Washout.
• Monitoring: Baseline and annual imaging (plain film for bone, MRI for cartilage if symptomatic), serial VAS pain and WOMAC scores, activity and exercise metrics.
• Stack layered on evidence-graded base: Weight management, structured exercise, topical/oral NSAIDs as needed, physical therapy, collagen peptides 10 g daily, Curcumin 500–1500 mg daily. The bioregulator rotation sits on top of this foundation.
• Coordinated with orthopaedics/rheumatology if established OA or inflammatory arthritis.
• Stop and reassess: If any cycle produces new joint symptoms, stop and evaluate. If imaging shows accelerated progression, reconsider whether bioregulators are adding value.
• Realistic expectation: Cartalax does not regrow cartilage. Best case is modest symptomatic improvement layered on an evidence-graded foundation.